Novosurge

Company Overview

Snapshot

Founded in January 2008 by Ehud Almon, Roni Shafir, and Dan Aravot, Novosurge operates with 1-10 employees. The company received a grant from the Office of the Chief Scientist.

Business overview

Novosurge is developing a robotic, structured incision system designed for precise, tailor-made hard-tissue incisions. Their core technology, the Structured Sternum Incision (SSI) platform, utilizes ultrasonic incising technology and an ultrasound imaging system to perform non-linear sternotomies with predetermined patterns and depths. This robotic-assisted surgery solution aims to improve sternal stability and reduce complications compared to existing midline sternotomy techniques. Novosurge operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices industry and healthcare providers with its medical treatment and therapeutics solutions.

Strategic signal

In November 2010, Medgadget reported on NovoSurge's development of a robotic Structured Sternotomy System for open-heart surgery. This system, which uses X-rays and ultrasounds to design a sinusoidal incision path, aims to enhance stability and decrease post-operative complications. The report highlights the company's innovative approach to surgical precision, signaling a potential advancement in medical technology for complex procedures, though it also noted the absence of efficacy studies and potential cost barriers at the time.

Company Intelligence Q&A

What is Novosurge's core technology?

Novosurge's core technology is the Structured Sternum Incision (SSI) platform, a robotic-assisted surgery solution that applies ultrasonic incising technology and an ultrasound imaging system to perform tailor-made, non-linear sternotomies.

When was Novosurge founded and by whom?

Novosurge was founded in January 2008 by Co-Founders Ehud Almon, Roni Shafir, and Dan Aravot.

What is the primary purpose of Novosurge's Structured Sternum Incision (SSI) platform?

The SSI platform is engineered to address the shortcomings of existing midline sternotomy techniques by creating a sinusoidal, adjustable incision that provides steadier and more accurate mutual positioning of sternal halves, preventing longitudinal slide and friction.

What is Novosurge's primary product?

Novosurge's primary product is the Structured Sternum Incision (SSI) platform, a robotic-assisted surgery solution that uses ultrasonic incising technology and an ultrasound imaging system to perform tailor-made, non-linear sternotomies.

What market does Novosurge primarily serve?

Novosurge primarily serves the Medical Devices industry and healthcare providers within the Health Tech & Life Sciences sector, focusing on medical treatment and therapeutics.